Who are Sonovue and Sonazoid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Contrast-Enhanced Ultrasound using Lumason, Optison echocardiography contrast agent, Perflutren lipid, Definity infusion, Contrast agent: SonoVue®., SonoVue®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sonovue-and-sonazoid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sonovue and Sonazoid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sonovue and Sonazoid (Sonovue and Sonazoid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ultrasound contrast agent. Area: Cardiology / Diagnostic Imaging.

phase 3 Ultrasound contrast agent Cardiology / Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Sonovue and Sonazoid (Sonovue and Sonazoid) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Sonovue and Sonazoid are ultrasound contrast agents that enhance echocardiographic and ultrasound imaging by producing microbubbles that reflect ultrasound waves.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Sonovue and Sonazoid TARGET	Sonovue and Sonazoid	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Ultrasound contrast agent
Contrast-Enhanced Ultrasound using Lumason	Contrast-Enhanced Ultrasound using Lumason	Children's Hospital of Philadelphia	marketed	Ultrasound contrast agent
Optison echocardiography contrast agent	Optison echocardiography contrast agent	University of Utah	marketed	Ultrasound contrast agent
Perflutren lipid	Perflutren lipid	UNC Lineberger Comprehensive Cancer Center	marketed	Ultrasound contrast agent
Definity infusion	Definity infusion	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	marketed	Ultrasound contrast agent
Contrast agent: SonoVue®.	Contrast agent: SonoVue®.	Centre Hospitalier Régional Metz-Thionville	phase 3	Ultrasound contrast agent
SonoVue®	SonoVue®	GE Healthcare	phase 3	Ultrasound contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ultrasound contrast agent class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 2 drugs in this class
Bracco Diagnostics, Inc · 1 drug in this class
Centre Hospitalier Régional Metz-Thionville · 1 drug in this class
Children's Hospital of Philadelphia · 1 drug in this class
GE Healthcare · 1 drug in this class
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 1 drug in this class
Sunnybrook Health Sciences Centre · 1 drug in this class
UNC Lineberger Comprehensive Cancer Center · 1 drug in this class
University of Utah · 1 drug in this class
Acusphere · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sonovue and Sonazoid — Competitive Intelligence Brief. https://druglandscape.com/ci/sonovue-and-sonazoid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab